| Patents for A61P 27 - Drugs for disorders of the senses (53,017) |
|---|
| 02/27/2001 | US6194401 Pharmaceutical compositions containing cyclosporine and a carrier comprising at least an ester of α-glycerophosphoric acid |
| 02/27/2001 | US6193957 For prophylaxis and therapy of airway hyperresponsiveness or inflammatory reactions, e.g., asthma, allergic rhinitis, allergic dermatitis, allergic conjunctivitis, inflammatory bowel disease or rheumatoid arthritis |
| 02/27/2001 | CA2188983C Pure 3r-3'r stereoisomer of zeaxanthin for treating macular degeneration in humans |
| 02/27/2001 | CA2081205C Steroids which inhibit angiogenesis |
| 02/22/2001 | WO2001012819A2 Protein phosphatases and diagnosis and treatment of phosphatase-related disorders |
| 02/22/2001 | WO2001012775A2 25 human secreted proteins |
| 02/22/2001 | WO2001012633A1 Water soluble sdz-rad esters |
| 02/22/2001 | WO2001012628A1 Pharmaceutical compositions containing thiazolidinedione derivatives and process for their preparation |
| 02/22/2001 | WO2001012618A1 Dihydroaminobenzo[b]- and [c]furans as retinoid-like agents |
| 02/22/2001 | WO2001012611A1 Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 02/22/2001 | WO2001012608A1 Quinoline compounds and process for producing the same |
| 02/22/2001 | WO2001012606A2 Tetrahydroquinoline derivatives having retinoid-like biological activity |
| 02/22/2001 | WO2001012598A2 METHODS OF INHIBITING BINDING OF β-SHEET FIBRIL TO RAGE AND CONSEQUENCES THEREOF |
| 02/22/2001 | WO2001012592A2 Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors |
| 02/22/2001 | WO2001012226A1 Angiogenesis inhibitors comprising as the active ingredient compound having chymase inhibitory effect |
| 02/22/2001 | WO2001012225A1 Water channel opener compositions and medicinal compositions for ophthalmic use |
| 02/22/2001 | WO2001012210A1 Methods and compositions useful for modulation of angiogenesis using tyrosine kinase raf and ras |
| 02/22/2001 | WO2001012195A2 Use of morphine derivatives as medicaments for the treatment of neuropathic problems |
| 02/22/2001 | WO2001012186A1 Cell adhesion inhibitors |
| 02/22/2001 | WO2001012179A1 Ophthalmic fluid |
| 02/22/2001 | WO2001012159A2 Artificial tear replacement solution |
| 02/22/2001 | WO2000071538A3 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives |
| 02/22/2001 | WO2000071514A8 α-AMINO-β-SULFONYL HYDROXAMIC ACID COMPOUNDS |
| 02/22/2001 | WO2000061122A3 Use of 6-methylmercaptopurine riboside in ophthalmologic compositions |
| 02/22/2001 | WO2000055126A3 N-cyanomethylamides as protease inhibitors |
| 02/22/2001 | WO1999063996A8 Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5ht2 receptors |
| 02/22/2001 | DE19939463A1 Tryptase inhibitors useful e.g. for treating inflammatory or allergic disease, arteriosclerosis or neoplasia, comprising new or known 2-phenethyl-benzimidazole-5-carboxamides |
| 02/22/2001 | DE19938668A1 Tränenersatzmittel Artificial tears |
| 02/22/2001 | CA2391319A1 Water soluble sdz-rad esters |
| 02/22/2001 | CA2382749A1 Amines substituted with a dihydro-isobenzofuranyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
| 02/22/2001 | CA2382148A1 25 human secreted proteins |
| 02/22/2001 | CA2382095A1 Methods of inhibiting binding of .beta.-sheet fibril to rage and consequences thereof |
| 02/22/2001 | CA2381976A1 Pharmaceutical compositions containing thiazolidinedione derivatives and process for their preparation |
| 02/22/2001 | CA2381971A1 Amines substituted with a tetrahydroquinolinyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological acitity |
| 02/22/2001 | CA2381551A1 Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 02/22/2001 | CA2380966A1 Methods and compositions useful for modulation of angiogenesis using tyrosine kinase raf and ras |
| 02/22/2001 | CA2380817A1 Cell adhesion inhibitors |
| 02/22/2001 | CA2380741A1 An ophthalmic fluid for contact lenses comprising a glyceride |
| 02/22/2001 | CA2378332A1 Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors |
| 02/22/2001 | CA2377662A1 Novel protein phosphatases and diagnosis and treatment of phosphatase-related disorders |
| 02/21/2001 | EP1077218A2 Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors |
| 02/21/2001 | EP1076665A1 Oral administration of immunoglobulins for treating autoimmune hearing loss |
| 02/21/2001 | EP1076557A1 Ccr-3 receptor antagonists |
| 02/21/2001 | CN1284947A Carboxyl acid substituted heterocycles as metalloproteinase inhibitors |
| 02/21/2001 | CN1284944A Integrin receptor antagonists |
| 02/21/2001 | CN1284874A 5-HT1F agonists |
| 02/21/2001 | CN1062165C Eye ointment for curing myopia and amblyopia |
| 02/21/2001 | CN1062164C Oral medicine pill for curing myopia and amblyopia |
| 02/21/2001 | CN1062148C Compound jiabing ear drops and preparation method thereof |
| 02/21/2001 | CN1062141C Potent pearl eye drops |
| 02/20/2001 | US6191147 Pyrazole compounds and uses thereof |
| 02/20/2001 | US6191135 Respiratory system disorders, antiinflammatory agents; analgesics |
| 02/20/2001 | US6191126 Topical administering |
| 02/20/2001 | US6190668 Providing cell mass of moraxella catarrhalis strain grown under iron-starved conditions to stimulate transferrin receptor protein expression; selectively extracting aqueous soluble proteins; separation; solubilizing; purification mass |
| 02/20/2001 | CA2223624C Tricyclic 5,6-dihydro-9h-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-.alpha.]pyridines |
| 02/20/2001 | CA2191789C Biaromatic compounds containing an adamantyl group in ortho position; pharmaceutical and cosmetic compositions containing them and use thereof |
| 02/15/2001 | WO2001010873A1 Novel 2-decarboxy-2-phosphinico prostaglandin f analogs |
| 02/15/2001 | WO2001010866A1 Interleukin-5 inhibiting 6-azauracil derivatives |
| 02/15/2001 | WO2001010859A1 Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity |
| 02/15/2001 | WO2001010833A1 Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain |
| 02/15/2001 | WO2001010442A1 Retinal ganglion cell death inhibitors containing dihydropyridine compounds |
| 02/15/2001 | WO2001010413A2 Periodic structures comprising lipids, polyelectrolytes, and structures-inducing soluble oligovalent linkers |
| 02/15/2001 | WO2001010409A1 Aqueous nasal formulation |
| 02/15/2001 | WO2001010406A2 Facilitating the preservation of sight by increasing optic nerve, choroidal and retinal blood flow |
| 02/15/2001 | WO2001010380A2 Benzanilides as potassium channel openers |
| 02/15/2001 | WO2000065054A3 Human membrane-associated proteins |
| 02/15/2001 | WO2000064946A3 Compositions and methods for cancer treatment by selectively inhibiting vegf |
| 02/15/2001 | WO2000057920A3 Method for expressing proteins |
| 02/15/2001 | DE19936719A1 Substituierte 1,5-Dihydropyrrol-2-on-Derivate Substituted 1,5-dihydropyrrol-2-one derivatives |
| 02/15/2001 | CA2381621A1 Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity |
| 02/15/2001 | CA2381033A1 Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain |
| 02/15/2001 | CA2380759A1 Interleukin-5 inhibiting 6-azauracil derivatives |
| 02/15/2001 | CA2378257A1 Method for increasing optic nerve, choroidal and retinal blood flow to facilitate the preservation of sight |
| 02/15/2001 | CA2378241A1 Benzanilides as potassium channel openers |
| 02/15/2001 | CA2377422A1 Periodic structures comprising lipids, polyelectrolytes, and structure- inducing soluble oligovalent linkers, and biological use thereof |
| 02/14/2001 | EP1075837A2 Process for the preparation of aqueous formulations for ophthalmic use |
| 02/14/2001 | EP1075493A2 Dna encoding snorf25 receptor |
| 02/14/2001 | EP1075476A1 Novel benzimidazoles and benzoxazoles |
| 02/14/2001 | EP1075472A1 Prodrugs of benzofuranylmethyl carbamate nk 1? antagonists |
| 02/14/2001 | EP1075285A1 The use of a vital dye for facilitating surgical procedures for cataract extraction |
| 02/14/2001 | EP1075277A2 Methods for detecting and inhibiting angiogenesis |
| 02/14/2001 | EP1075265A1 Use of tetracyclines for treating meibomian gland disease |
| 02/14/2001 | EP1075256A1 Arylhydrocarbon receptor ligand antagonists |
| 02/14/2001 | EP0844874A4 METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF ALPHA v BETA 5 MEDIATED ANGIOGENESIS |
| 02/14/2001 | CN1284134A Methods of producing anti-angiogenic proteins: endostation, angiostation or restin, using pichia yeast expression system |
| 02/14/2001 | CN1284130A Mutants of endostation, 'EM1' having ant-angiogenic activety and methods of use thereof |
| 02/14/2001 | CN1284077A Purine derivatives having phosphodiesterase IV inhibition activity |
| 02/14/2001 | CN1284073A 5-(2-imidazolinylamino)-benzimidazole derivatives, their prepn. and their use as alpha-adrenoceptor agonists with inproved metabolic stability |
| 02/14/2001 | CN1284066A Substituted inidazole derivatives having agonist-like activity at alpha 2B or 2B/2C adrenergic receptors |
| 02/14/2001 | CN1283992A Sustained release drug delivery device |
| 02/14/2001 | CN1283623A 1,2,4,5-tetrahydro-benzo[d] azepine compound |
| 02/14/2001 | CN1283477A 'Yanming' capsules for clearing eyes |
| 02/14/2001 | CN1283476A 'Qingzhang Hingmu' pills for clearing eyes |
| 02/14/2001 | CN1283465A Chinese Medicine for curing cataract and its preparing process |
| 02/14/2001 | CN1061879C Chinese medicinal drug for preventing and treating catarct and its prepn method |
| 02/14/2001 | CN1061874C Vision recovering capsule and its preparing method |
| 02/13/2001 | US6187803 Treating allergic disease, autoimmune disease, immunodeficiency syndrome, inflammatory disease or eosinophilia by orally administering a histamine-added immunoglobulin and carrier; tablets, capsules |
| 02/13/2001 | US6187798 Heterocyclic compounds |
| 02/13/2001 | CA2170065C Amide-derived bi-aromatic compounds; pharmaceutical and cosmetic compositions containing the same and their uses |
| 02/09/2001 | CA2315594A1 Process for the preparation of aqueous formulations for ophthalmic use |